Advertisement

Wall Street and its analysts bestow some love on Cynosure as the company reports its 4th consecutive expectation-beating quarter.

CynoSure logo

Aesthetics devices maker Cynosure (NSDQ:CYNO) got some Wall Street love after the company reported strong 3rd-quarter financials, marking the 4th quarter in a row that Cynosure has beat expectations.

Wall Street analysts maintained their optimistic outlook on the company as well, with Leerink Swann analysts reiterating an "outperform" rating as Cynosure looks forward to a pair of new product launches in 2013.

Cynosure expects some time in 2013 to win FDA approval for its Picosure laser system, with indication to remove tattoos and pigmented lesions, and the company is preparing to launch its 1st home-use aesthetic device, which already won FDA clearance earlier this year.

Advertisement
Advertisement